Travecta Therapeutics, Pte Ltd. incorporated in Singapore on 7th April 2017, a preclinical stage biopharmaceutical company
SINGAPORE, June 9, 2021 Travecta Therapeutics, Pte Ltd. incorporated in Singapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of Charles S. Ryan, JD, PhD as President and Chief Executive Officer. Dr. Ryan recently served as Chief Executive Officer and Director of Neurotrope, Inc. In his new role, Dr. Charles Ryan will work closely with the scientific team to develop novel therapeutics to tackle some of the biggest challenges facing patients suffering from pain and debilitating brain disorders. The company’s current development plan anticipates its lead compound candidate for pain will be first administered to humans during the first quarter of 2022.
“Travecta is at a major inflection point in its evolution, leveraging recent scientific insights in our platform technology mVECTA
“Travecta Therapeutics presents a unique opportunity to build a company with a platform technology that can deliver drugs to the brain, offering one of the most promising therapeutic approaches to managing pain and improving cognition in patients with a variety of Central Nerves System (CNS) disorders and neurodegenerative disease,” said Dr. Ryan, “I am honored to have an opportunity to lead Travecta and am looking forward to recruiting an experienced management team comprised of individuals who are committed to the company’s mission to develop novel therapeutics that can improve the lives of patients suffering from pain and other cognitive and debilitating illnesses.”
Dr. Ryan brings an extensive background in pharmaceuticals and biotechnology. Most notably, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years, where he managed several intellectual property estates. Dr. Ryan worked closely with the commercial and development teams as well as the business development teams at Forest. Most recently, he served as CEO and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company leveraging Bryostatin-1 and its analogues to discover and develop targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Still prior, Dr. Ryan served as President, CEO and Director of Orthobond, Inc., a biotechnology company that has developed proprietary antimicrobial nanosurfaces with broad applications in the medical device industry.
About Travecta Therapeutics
Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier. The company’s proprietary platform mVECTA
For more information, visit: https://travectatherapeutics.com/.
This news is shared to Prittle Prattle News via a press release.
By PR Newswire